Anti-inflammatory and antioxidative effects of genistein in a model of spinal cord injury in rats

Ercan Bal¹,²,*, Şahin Hanalioğlu³, Aydin Sinan Apaydin², Ceylan Bal⁴, Almila Şenat⁵, Berrak Gümüşkaya Öcal⁵, Burak Bahadır², Ömer Faruk Türkoğlu⁵

Abstract

Background: Neurological damage from spinal cord injury (SCI) is a result of primary mechanical injury and secondary damage from oxidative stress and neuroinflammation. Although genistein has been shown to have potent antioxidant and anti-inflammatory effects in studies of brain injury, its effect on secondary damage in SCI has remained unknown.

Objective: To determine effects of genistein in a model of SCI in rats.

Methods: We divided 21 rats evenly into 3 groups, a control group, in which only a laminectomy was performed; a trauma group in which SCI was induced; and a genistein group in which genistein was administered subcutaneously after SCI. The rats were assessed using a Basso–Beattie and Bresnahan functional score at the 12th hour and on the 1st, 3rd, 5th, and 7th days. Biochemical analyses were conducted at the same time points to determine the serum levels of catalase, ischemia-modified albumin (IMA), disulfide (SS), total thiol (TT), native thiol (NT), disulfide/total thiol (SS/TT), and native thiol/total thiol (NT/TT). Total oxidant and antioxidant capacity, and oxidative stress index were determined in spinal cord tissue obtained on the 7th day together with immunohistochemistry for cyclooxygenase-2 levels.

Result: Catalase activity on the 7th day was significantly (P = 0.001) higher in the genistein-treated rats than in other groups, and IMA levels became stable earlier (3rd day) in the genistein group. SS values were significantly (P = 0.004) lower in the genistein group. NT/TT ratio were significantly (P = 0.049) higher in the genistein-treated rats on the 7th day.

Conclusion: Genistein has antioxidant, anti-inflammatory, and protective effects in a model of SCI in rats and warrants further study.

Keywords: antioxidants; genistein; oxidative stress; spinal cord injuries; sulphydryl compounds
that are usually eliminated after being converted into O₂ and 
H₂O₂ via antioxidant enzymes such as superoxide dismutase, 
glutathione peroxidase, and catalase. Oxidative stress creates 
an imbalance between oxidants and antioxidants at the cellular 
level. An antioxidant defense system protects cells by neutral-
izing the harmful effects of oxidants and free radicals and 
high levels of antioxidants have been found in the spinal cord 
[5, 6]. If an appropriate antioxidant response is not obtained 
following SCI, further cellular damage occurs, contributing to 
a positive feedback cycle resulting in further oxidative stress 
[5]. Oxidative stress is an ongoing process throughout both 
primary and secondary damage, and the severity and un-
controlled nature of oxidative stress are related to the magnitude 
of the damage [1, 4–6]. Thus, markers of oxidative stress have 
been used to monitor SCI and response to treatment [7–9], and 
many studies have focused on resolving inflammation and 
antioxidant therapies for traumatic brain and SCI [6, 10].

Genistein, a phytoestrogen, is an isoflavonoid found in 
high concentrations in soybeans [11–13]. Genistein has been 
shown to reduce the risk of cancers such as those of the breast 
and prostate, which are associated with estrogen [11]. In 
addition, positive effects on bone mineral development, anti-
menopausal effects, and antioxidant and anti-inflammatory 
effects have been reported [13–20]. Although genistein has 
been shown to have potent antioxidant and anti-inflammatory 
effects in several studies of brain injury [16, 17], to our know-
ledge, its effect on SCI-induced damage remains unknown. 
In the present study, the antioxidant and anti-inflammatory 
effects of genistein were investigated in a model of SCI in 
rats, and its contribution to the recovery of the spinal cord was 
evaluated biochemically, histopathologically, and functionally 
through oxidant and antioxidant markers.

Methods

The protocols for this study were approved by the local ethics 
committee of Kobay Deney Experimental Animals Laboratory 
(No. 280). All protocols followed national guidelines for the 
care and use of laboratory animals and were compliant with the 
U.S. Health Research Extension Act (Public Law 99–158, 
1985 “Animals in Research”). Reporting follows ARRIVE 
2.0 guidelines [21]. Adult female Wistar–Hannover albino 
rats (each weighing 250–300 g; n = 21) were separated into 
3 groups of 7 rats without selection. During the experiments, 
al rats were kept in a standard postoperative care room (at 
20–25 °C with 50%–60% humidity grouped in polycarbonate 
cages) and allowed standard feed, under 12-h light and dark 
cycles.

A commercial kit was used to determine the total anti-
oxidant status (TAS) and total oxidative status (TOS) in the 
tissue [22, 23]. Tissue protein was assayed using the Lowry 
method [24]. Oxidative stress index (OSI) was obtained by 
dividing TOS values by TAS values [OSI (arbitrary Unit) = 
(TOS, μmol H₂O₂ eq/L)/(TAS, μmol Trolox eq/L)].

Serum thiol–disulfide (SS) was measured with an auto-
matic analyzer (Cobas 501; Roche) using a method devel-
oped by Erel and Neselioglu [25]. Briefly, disulfide bonds in 
the sample were converted into functional thiol groups with 
NaBH₄. The total thiol (TT) content in the sample was calcula-
ted using a modified Ellman reagent. Serum disulfide amount 
was determined using the following formula: (serum TT – 
serum native thiol [NT])/2.

Serum ischemia-modified albumin (IMA) levels were 
determined according to the Bar–Or method [26]. The results 
are expressed in absorbance units (AbsU). Serum cata-
lytase activity was measured using a method described by Göth [27].

Experiment

The rats were separated into 3 equal number groups without 
selection (A: control group, B: weight-drop group, C: geni-
stein group) (Figure 1). After 6 h of fasting, 1 mg/kg of keta-
mime (Ketalar, Pfizer) and 1 mg/kg of xylazine (Alfazyne, 
Alfasan) were administered intraperitoneally. The rats were 
allowed spontaneous breathing, and T7-8-9 laminectomies 
were conducted in accordance with standard surgical proce-
dures. Analgesic agents were not used during the recovery 
process because we sought to evaluate anti-inflammatory 
markers.

- In the control group (n = 7), only a T7-8-9 laminectomy 
  was performed.
- In the trauma group (n = 7), after a T7-8-9 laminectomy, 
  trauma was induced with a modified Allen weight-drop 
  apparatus. Using a glass tube with a diameter of 0.5 cm 
  and a length of 10 cm, a 10 g weight was dropped on the 
  intact dura from a height of 10 cm.
- In the genistein group (n = 7), a T7-8-9 laminectomy was 
  performed, and spinal trauma was induced as described 
  above. Rats in this group were administered a first dose 
  of genistein (Sigma-Aldrich; 2 mg/kg subcutaneously) at 
  15 min immediately after trauma and further administra-
  tion of genistein at 2 mg/kg/day for 7 days.

After deep general anesthesia with 1 mg/kg of ketamine 
and 1 mg/kg of xylazine the rats were killed on the 7th day by 
transcardiac perfusion with saline followed by phosphate-buf-
fered 4% paraformaldehyde (in 0.1 mol/L phosphate-buffered 
saline, pH 7.4), and their spinal cords removed. No rats died 
unintentionally, and no infection or serious adverse events 
were observed during the experiment.
Effect of genistein in spinal cord injury

Figure 1. Timeline for the experiment. In group A (n = 7, control group, only T7-8-9 laminectomy), in group B (n = 7, trauma group, after T7-8-9 laminectomy and trauma was induced with a modified Allen weight-drop method, in group C (n = 7, genistein group, T7-8-9 laminectomy and spinal trauma was induced as described above. It was planned that group C would receive the first dose of genistein at 15 min immediately after trauma and would be given genistein subcutaneously at 2 mg/kg/day for 7 days). The rats were killed on the 7th day and the spinal cord was removed as a whole. No rats were lost, and no infection, or additional problems were observed during the experiment. cat, catalase; Cox-2, cyclooxygenase-2; IMA, ischemia-modified albumin; NT, native thiol; OSI, oxidative stress index; SS, disulfide; TT, total thiol; TAS, total antioxidant status; TOS, total oxidative status.

Biochemical analysis

Tail blood was taken before anesthesia, at the 12th hour, and on the 1st, 3rd, 5th, and 7th days after the surgical procedure. Catalase, IMA, and thiol-disulfide balance were assayed. After killing the rats on the 7th day, the spinal cord tissue in the T7-8-9 region was removed, and TOS and antioxidant capacity (TAS), and OSI determined in the spinal cord tissue samples.

Functional analysis

Basso–Beattie and Bresnahan (BBB) scores were examined in all rats at baseline and the 12th hour, and on the 1st, 3rd, 5th, and 7th days. The results were evaluated statistically [28, 29].

Histopathology

After the rats were killed on the 7th day, their entire spinal cords were removed. Next, 1-cm specimens from the traumatized site of each spinal cord were obtained and put into phosphate-buffered 10% formaldehyde. On gross dissection, sections of spinal cords cut perpendicularly were processed and embedded in paraffin blocks. Then, 4-μm sections were deparaffinized in xylene and rehydrated through a graded series of ethanol before hematoxylin and eosin staining and immunohistochemistry.

Immunohistochemistry was performed using a mouse monoclonal cyclooxygenase-2 (Cox-2) antibody (clone D-12: catalog No. sc-166475, Santa Cruz Biotechnology; Research Resource Identifier (RRID): AB_227666) primary
antibody with a Leica Bond-Max auto-stain detection system (catalog No. DS9800, Leica) according to the manufacturer’s instructions.

A pathologist, who was blinded to the groups, examined the immunohistochemically stained sections. Cox-2 immunoreactive (IR) cells were counted per 3 high powered fields (HPFs Olympus BX51 microscope 400×) for each spinal cord.

Statistical analyses

Data were analyzed using IBM SPSS Statistics for Windows (version 25). Data are expressed as mean ± standard deviation (SD) or median (interquartile range; Q1, Q3). A one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc test and a Kruskal–Wallis test followed by a Dunn post hoc test were used to analyze differences between independent variables. A repeated measures ANOVA and Friedman analyses with Bonferroni post hoc correction were used to determine the differences between the dependent variables. Differences with \( P < 0.05 \) were considered as significant.

Results

Biochemical findings

Catalase

There was no significant difference in the baseline serum activity between the groups. Although no significant difference \( (P = 0.109) \) was found between the groups at the 12th hour, on the 1st day the activity in the control group (A) was significantly lower \( (P = 0.001) \) than that in the trauma group (B) and genistein group (C), and activity in group B was significantly lower \( (P = 0.001) \) than that in group C. Compared with the baseline, catalase activity was decreased slightly in group A, increased slightly in group C, and increased in group B at the 12th hour. On the 1st day, catalase activity decreased in groups A and B and increased in group C, and was significantly different between the groups \( (P = 0.001) \). A significant difference \( (P = 0.001) \) was also found on the 7th day. Compared with the baseline, catalase activity increased slightly in group A, decreased in group B, and increased significantly in group C on the 7th day (Table 1, Figure 2).

IMA

No significant difference in serum levels of IMA was observed between the 3 groups at baseline \( (P > 0.05) \). At the 12th hour, the level in the control group (A) was significantly lower \( (P = 0.001) \) than those in groups B and C, whereas there was no significant difference in levels between groups B and C. At the 12th hour, the IMA level had decreased in group A, whereas it had increased slightly in groups B and C. The lower level in group A compared with levels in groups B and C at the 12th hour, increased to be significantly higher \( (P < 0.001) \) than those in groups B and C on the 1st day. A comparison of the IMA levels at the 12th hour and on the 7th day after trauma demonstrated that there was no significant difference in the levels in groups A and B; however, the level in group C was significantly higher \( (P = 0.004) \) on the 7th day. In group B, IMA plateaued on the 5th day, whereas it plateaued on the 3rd day in groups A and C (Table 1).

Disulfide (SS)

There was no significant difference in the baseline serum SS serum levels between the groups. No significant difference \( (P = 0.29) \) was found between the levels at the 12th hour. A significant difference was observed on the 1st, 5th, and 7th days between the control group (A) (lower) and trauma group (B) \( (P = 0.004) \) and genistein group (C) \( (P = 0.014) \), and between groups B (higher) and C \( (P = 0.004) \). Compared with the baseline, on the 7th day there was no significant difference in the SS levels in group A, whereas we observed a significant increase in group B, and a significant decrease in group C (Table 1, Figure 3).

Native thiol (NT)

There was no significant difference in the baseline serum levels of NT between the groups. The level of NT in group C was significantly lower than those of groups A and B at the 12th hour \( (P = 0.007) \) and higher on the 1st day \( (P = 0.002) \) and lower on the 7th day \( (P = 0.001) \). NT levels fluctuated with temporal increases and decreases (Table 1).

Total thiol (TT)

There was no significant difference in the baseline TT serum levels between the groups. A significant difference in TT values was observed between the groups at the 12th hour \( (P = 0.007) \), 1st day \( (P = 0.04) \), and 7th day \( (P < 0.001) \). On the 7th day, the level of TT was significantly lower in the genistein group (C) than it was in the control (A) and trauma (B) groups, and lower in group A than in group B, which had the highest level of TT \( (P < 0.001) \). TT levels fluctuated with temporal increases and decreases (Table 1).
| Parameter | Group | Baseline | 12th hour | 1st day | 3rd day | 5th day | 7th day | P       |
|----------|-------|----------|-----------|---------|---------|---------|---------|---------|
| Catalase (kU/L) | A | 79.0 ± 18.0 | 74.2 ± 9.2 | 31.5 ± 13.8 | 84.3 ± 6.1 | 61.7 ± 12.0 | 86.0 ± 10.0 | <0.001 |
| B | 48.1 ± 9.9 | 74.9 ± 7.9 | 42.6 ± 9.2 | 48.0 ± 4.6 | 54.1 ± 12.3 | 37.9 ± 21.9 | 0.02    |
| C | 51.4 ± 11.9 | 51.8 ± 30.0 | 76.9 ± 13.9 | 69.4 ± 13.3 | 75.0 ± 9.1 | 75.0 ± 9.1 | 0.002   |
| P | 0.11 | 0.11 | 0.001 (x, z) | 0.15 (x, y, z) | 0.15 | 0.001 (x, z) |         |
| Ischemia-modified albumin (AbsU) | A | 0.84 ± 0.05 | 0.82 ± 0.05 | 0.99 ± 0.05 | 0.93 ± 0.04 | 0.91 ± 0.05 | 1.01 ± 0.03 | <0.001 |
| B | 0.87 ± 0.04 | 0.93 ± 0.03 | 0.91 ± 0.03 | 0.78 ± 0.08 | 0.92 ± 0.04 | 0.92 ± 0.03 | 0.001   |
| C | 0.91 ± 0.03 | 0.92 ± 0.04 | 0.85 ± 0.04 | 1.00 ± 0.04 | 0.98 ± 0.05 | 1.07 ± 0.09 | <0.001  |
| P | 0.10 | 0.001 (x, y) | <0.001 (x, y, z) | <0.001 (x, y, z) | 0.10 | 0.004 (x, z) |         |
| NT (mmol/L) | A | 183.1 ± 37.8 | 110.9 ± 36.0 | 116.0 ± 16.2 | 71.7 ± 13.3 | 157.3 ± 26.0 | 87.4 ± 20.4 | <0.001 |
| B | 190.8 ± 51.0 | 222.2 ± 27.1 | 96.0 ± 31.4 | 127.8 ± 24.3 | 130.7 ± 29.8 | 166.3 ± 22.5 | <0.001  |
| C | 194.7 ± 38.7 | 99.9 ± 37.6 | 167.3 ± 24.7 | 99.8 ± 32.4 | 108.1 ± 28.6 | 71.2 ± 22.9 | <0.001  |
| P | 0.91 | 0.007 (x, y) | 0.002 (y, z) | 0.006 (x) | 0.02 (y) | 0.001 (x, z) |         |
| TT (mmol/L) | A | 250.3 ± 53.0 | 189.4 ± 47.5 | 158.5 ± 18.2 | 142.4 ± 12.5 | 202.5 ± 33.0 | 152.3 ± 21.0 | 0.002 |
| B | 248.1 ± 63.7 | 281.7 ± 29.4 | 182.8 ± 54.5 | 207.4 ± 31.4 | 213.0 ± 42.6 | 238.4 ± 40.4 | 0.02    |
| C | 245.0 ± 55.7 | 170.8 ± 23.0 | 210.4 ± 28.2 | 160.1 ± 40.3 | 187.7 ± 42.9 | 106.0 ± 19.7 | 0.02    |
| P | 0.99 | 0.007 (x, z) | 0.002 (y) | 0.01 (x) | 0.01 (x, y) | 0.004 (x, z) |         |
| SS (mmol/L) | A | 33.6 ± 10.2 | 39.2 ± 9.5 | 21.2 ± 6.1 | 35.3 ± 5.2 | 22.6 ± 5.0 | 32.4 ± 8.4 | 0.007 |
| B | 28.6 ± 11.3 | 29.8 ± 8.8 | 43.4 ± 14.0 | 39.8 ± 12.5 | 41.2 ± 17.6 | 36.1 ± 11.7 | 0.33    |
| C | 25.2 ± 10.5 | 35.5 ± 18.4 | 21.6 ± 4.2 | 30.2 ± 8.7 | 39.8 ± 9.6 | 17.4 ± 8.5 | 0.005   |
| P | 0.297 | 0.286 | 0.004 (x, z) | 0.193 | 0.014 (x, y) | 0.004 (x, z) |         |
| NT/TT (%) | A | 73.4 ± 5.0 | 57.9 ± 6.7 | 73.3 ± 6.9 | 50.2 ± 7.3 | 77.7 ± 3.0 | 57.4 ± 9.8 | <0.001 |
| B | 77.1 ± 5.6 | 78.9 ± 5.7 | 525 ± 7.5 | 62.0 ± 9.8 | 62.1 ± 12.3 | 70.2 ± 5.7 | <0.001  |
| C | 70.0 ± 4.9 | 58.6 ± 18.9 | 79.5 ± 3.1 | 61.6 ± 11.5 | 57.4 ± 6.5 | 66.9 ± 18.5 | <0.001  |
| P | 0.12 | 0.003 (x, z) | 0.001 (x, z) | 0.04 (x, y) | 0.005 (x, y) | 0.049 (x) |         |
| SS/TT (%) | A | 13.3 ± 2.5 | 21.0 ± 3.4 | 13.3 ± 3.5 | 24.9 ± 3.7 | 11.2 ± 1.5 | 21.3 ± 4.9 | <0.001 |
| B | 11.5 ± 2.8 | 10.5 ± 2.8 | 23.8 ± 3.7 | 19.0 ± 4.9 | 18.9 ± 6.2 | 14.9 ± 2.9 | <0.001  |
| C | 10.0 ± 2.5 | 20.7 ± 9.5 | 10.3 ± 1.5 | 19.2 ± 5.7 | 21.3 ± 3.2 | 16.6 ± 9.2 | <0.001  |
| P | 0.11 | 0.003 (x, z) | 0.001 (x, z) | 0.04 (x, y) | 0.005 (x, y) | 0.049 (x) |         |
| SS/NT (%) | A | 18.4 ± 4.7 | 37.3 ± 9.8 | 18.8 ± 7.0 | 51.7 ± 16.3 | 14.5 ± 2.5 | 39.7 ± 17.6 | <0.001 |
| B | 15.2 ± 5.1 | 13.6 ± 4.6 | 46.9 ± 13.5 | 32.6 ± 13.9 | 33.5 ± 18.5 | 21.6 ± 5.6 | <0.001  |
| C | 12.7 ± 3.7 | 45.2 ± 36.4 | 13.0 ± 2.5 | 34.6 ± 22.1 | 38.2 ± 10.4 | 31.1 ± 28.5 | 0.001   |
| P | 0.12 | 0.003 (x, z) | 0.001 (x, z) | 0.04 (x, y) | 0.005 (x, y) | 0.052 (x) |         |

Group A, control group; group B, trauma group; group C, genistein group; x, significant difference between groups A and B; y, significant difference between groups A and C; z, significant difference between groups B and C; P, a one-way ANOVA followed by a Bonferroni post hoc test and a Kruskal–Wallis test followed by a Dunn post hoc test were used to determine differences between independent variables. A repeated measures ANOVA and Friedman analyses with Bonferroni post hoc correction were used to determine differences between dependent variables. P < 0.05 was considered significant.

AbsU, absorbance units; NT, native thiol; NT/TT, native thiol/total thiol; SS, disulfide; SS/TT, disulfide/total thiol; TT, total thiol.
Bal et al.

Native thiol/total thiol (NT/TT)

No significant difference in ratios was observed between the groups at baseline. There was a significant difference between the groups at all time points (12th hour, \( P = 0.003 \); 1st day, \( P = 0.001 \); 3rd day, \( P = 0.04 \); 5th day, \( P = 0.005 \); 7th day, \( P = 0.049 \)). There was no significant difference in the control group (A) on the 7th day compared with the ratio at the 12th hour, whereas there was a decrease in the trauma group (B) and an increase in the genistein group (C) (Table 1).

Disulfide/total thiol (SS/TT)

No significant difference in the ratio was observed between the groups at baseline. There was a significant difference in the ratio between the groups at all time points (12th hour, \( P = 0.003 \); 1st day, \( P = 0.001 \); 3rd day, \( P = 0.04 \); 5th day, \( P = 0.005 \); 7th day, \( P = 0.049 \)). Compared with the baseline, although an increase in the ratio was found on the 7th day for all groups, there was no significant difference from the ratio at the 12th hour in the control group (A); whereas, an increase in the ratio was found in the trauma group (B), and a decrease in the genistein group (C) (Table 1).

TAS, TOS, and OSI

These parameters were evaluated in the spinal cord tissue obtained on the 7th day. There was no significant difference between the groups for TAS \(( P = 0.26)\), TOS \(( P = 0.40)\), or OSI \(( P = 0.56)\) (Table 2).

Catalase

Group A: serum catalase activity on the 1st day was significantly lower than that at baseline, at the 12th hour, and activity on the 3rd and 7th days. Activity on the 5th day was

![Figure 2. Catalase serum levels. Significant difference was observed on the 7th day \(( P = 0.001)\). Compared with the baseline, serum catalase values increased slightly in the control group (A white bars), decreased in the trauma group (B light gray bars), and increased significantly in the genistein group (C dark gray bars) on the 7th day. B, baseline; 0.5, 12th hour. Bars indicate means. Error bars (SD).](image)

![Figure 2. Catalase serum levels. Significant difference was observed on the 7th day \(( P = 0.001)\). Compared with the baseline, serum catalase values increased slightly in the control group (A white bars), decreased in the trauma group (B light gray bars), and increased significantly in the genistein group (C dark gray bars) on the 7th day. B, baseline; 0.5, 12th hour. Bars indicate means. Error bars (SD).](image)

Table 2.

|                      | Control group (A) | Trauma group (B) | Genistein group (C) | \( P \) |
|----------------------|-------------------|------------------|---------------------|--------|
| TAS (nmol Trolox Eq/mg protein) | 35.8 (30.7–40.8) | 32.7 (28.6–36.8) | 30.8 (29.8–35.3) | 0.26   |
| TOS (nmol H₂O₂ Eq/mg protein) | 1.08 (0.59–1.12) | 0.67 (0.58–0.85) | 0.83 (0.60–1.11) | 0.40   |
| OSI (TOS/TAS)        | 0.03 ± 0.01       | 0.02 ± 0.01      | 0.03 ± 0.01         | 0.56   |
| Cox 2 IR cells/3 HPFs | 19.1 ± 5.3        | 17.1 ± 5.9       | 7.71 ± 5.0          | 0.008 (y, z) |

Data are expressed as mean ± SD or median (Q1, Q3). Cox-2, cyclooxygenase-2; HPF, 400× high-powered field; IR, immunoreactive; OSI, oxidative stress index; TAS, total antioxidant status; TOS, total oxidative status; \( x \), significant difference between groups A and B; \( y \), significant difference between groups A and C; \( z \), significant difference between groups B and C. Repeated measures ANOVA and Friedman analyses for (dependent) variables within the groups are indicated as follows (Table 1).
significantly lower than that on the 3rd and 7th days. Group B: the activity at the 12th hour was significantly higher than that at baseline, and on the 1st, 3rd, 5th, and 7th days. Group C: the activity at baseline and at the 12th hour was significantly lower than that on the 1st, 3rd, 5th, and 7th days (Figure 2).

**IMA**

Group A: baseline and 12th hour levels were significantly lower than those on the 1st, 3rd, 5th, and 7th days. Group B: the IMA level on the 3rd day was significantly lower than that on the 1st and 5th days. Group C: the level on the 1st day was significantly lower than that on the 1st, 3rd, and 7th days.

**Native thiol**

Group A: the serum NT level at baseline was significantly higher than that at the 12th hour, and on the 1st, 3rd, and 7th days. The level on the 3rd day was significantly lower than that at the 12th hour, and on the 1st and 5th days. The level on the 5th day was significantly higher than that on the 1st day. Group B: the levels at baseline and at the 12th hour were significantly higher than those on the 1st, 3rd, and 5th days. The level on the 1st day was significantly higher than those on the 3rd, 5th, and 7th days. Group C: the serum level on the 7th day was significantly lower than that at baseline and on the 1st day.

**Total thiol**

Group A: the serum level of TT at baseline was significantly higher than that at the 12th hour, and on the 1st, 3rd, 5th, and 7th days. The level on the 3rd day was significantly lower than that at the 12th hour, and on the 1st and 5th days. Group B: the level at the 12th hour was significantly higher than that on the 1st and 3rd days. Group C: the serum level of TT on the 7th day was significantly lower than that at baseline, at the 12th hour, and the levels on the 1st, 3rd, and 5th days.

**Disulfide**

Group A: the level of serum disulfide at the 12th hour was significantly higher than that on the 1st and 5th days. Group B: no significant temporal differences in serum disulfide levels were found. Group C: the level on the 5th day was significantly higher than that on the 1st and 7th days (Figure 3).

**NT/TT**

Group A: the ratio at the 12th hour, and those on the 3rd and 7th days were significantly lower than those at baseline, and on the 1st and 7th days. Group B: the ratio on the 1st day was significantly lower than that at baseline and at the 12th hour. Group C: the ratios at the 12th hour and on the 5th day were significantly lower than those at baseline and on the 1st day.

**SS/TT**

Group A: the ratio on the 3rd day was significantly higher than that at baseline, and on the 1st and 5th days. The ratio on the 5th day was significantly lower than that at the 12th hour and on the 7th day. Group B: the ratio on the 1st day was significantly higher than that at baseline, at the 12th hour, and on the 7th day. Group C: the ratio at the 12th hour was significantly higher than that at baseline and on the 1st day.

**SS/NT**

Group A: the ratio on the 3rd day was significantly higher than that at baseline, and on the 1st and 5th days. The ratio on the 5th day was significantly lower than that at the 12th hour and on the 7th day. Group B: the ratio on the 1st day was significantly higher than that at baseline, at the 12th hour, and on the 7th day. Group C: the ratio at the 12th hour was significantly higher than that at baseline and on the 1st day.

**Immunohistopathology**

A significant difference was found between the groups ($P = 0.008$). The highest numbers of Cox-2 IR cells per 3 HPFs were observed in the control (A) and trauma (B) groups. The lowest numbers of Cox-2 IR cells per 3 HPFs were observed in the genistein group (C) (Table 2, Figures 4 and 5).

**Functional findings**

At the 12th hour, the trauma (B) and genistein (C) groups had significantly ($P = 0.006$) poorer BBB scores than the control group (A). On the 1st day, the scores in the control group (A) were significantly higher ($P = 0.002$) than those in groups B and C, whereas there was no significant difference between groups B and C ($P > 0.05$). The scores in the genistein group (C) were significantly higher than those in the trauma group (B) on the 3rd ($P = 0.001$), 5th ($P < 0.001$), and 7th days.
Figure 4. Immunohistochemically stained rat spinal cord sections with hematoxylin and eosin counterstain. A mouse monoclonal Cox-2 antibody (clone D-12; catalog No. sc-166475, Santa Cruz Biotechnology; RRID: AB_2276666) was used for primary detection, the monoclonal antibody was visualized using a diaminobenzidine chromogen system showing brown staining. Cox-2 positive cells were counted per 3 HPFs for each spinal cord (left panel, trauma group (B), right panel, genistein group (C). Left panel scale bar indicates 0.5 mm, inset scale bar indicates 50 μm. Right panel scale bar indicates 0.5 mm. Cox-2, cyclo-oxygenase-2; HPFs, 400× high-powered fields; RRID, research resource identifier.

Friedman analyses of BBB scores were as follows. Group A: 12th hour score was significantly lower than that on the 1st, 3rd, 5th, and 7th days. The score on the 7th day was significantly higher than that on the 1st, 3rd, 5th days. Group B: 12th hour score was significantly lower than that on the 1st, 3rd, 5th days. The score on the 7th day was significantly higher than that on the 1st, 3rd, 5th days. Group C: 12th hour score was lower than that on the 1st, 3rd, 5th days. The score on the 7th day was significantly higher than that on the 1st, 3rd, 5th days (Table 3).

Discussion

In the present study, although there was no difference between the groups at the 12th hour ($P > 0.05$), significant differences were noted in favor of the genistein group after the 1st day ($P = 0.001$). Compared with baseline, the highest increase in serum catalase level was observed in the genistein group on the 7th day. Treatment with genistein was not associated with significant change during the early period (12th hour), but was associated with a significantly higher catalase level on the 7th day (Table 1, Figure 2). Considering catalase levels, antioxidant capacity increased in the genistein group. A low level of

Figure 5. Cox-2 immunoreactivity scoring. Significant difference ($P = 0.008$) was found between the genistein (C) and other groups (A, B). The highest number of Cox-2 IR cells per 3 HPFs was observed in the control group (A white bar) and the trauma group (B light gray bar). The lowest number of Cox-2-IR cells was observed in the genistein group (C dark gray bar). Bars indicate means. Error bars (SD). Cox-2, cyclo-oxygenase-2; HPFs, 400× high-powered fields; IR, immunoreactive.

(P < 0.001). The significantly higher score in the control group (A) compared with the score in the genistein group (C) found at the 12th hour and 1st day, was not found on the 5th or 7th days ($P > 0.05$) (Table 3).
catalase has been reported in spinal cord injuries, and catalase has been used to monitor treatment response [30–32].

IMA has been considered as a marker of oxidative processes. Oxygen radicals resulting from trauma damage the N-terminal of albumin under ischemic conditions and form a variant protein known as IMA. Clinical studies have found that its levels increase 6–12 h after an ischemic event, and return to baseline after 24 h [33, 34]. IMA can be used with high sensitivity and specificity in predicting mortality and damage in severe traumatic brain injury [34]. Because free oxygen radicals occur as a result of oxidative stress in secondary damage after SCI, it is believed that IMA levels may also be used as an early indicator of the damage [35]. In the present study, when the trauma and control groups were compared, a significant difference was found between the 2 groups, particularly in the early period of injury (at the 12th hour and on the 1st day), and this difference became highly significant on the 1st day. The course of IMA showed a similar pattern in the control and genistein groups, but a different pattern was observed in the trauma group. Although IMA plateaued in the trauma group on the 5th day, it plateaued on the 3rd day in the control and genistein groups (Table 1). IMA levels stabilized earlier in the control and genistein groups, but a different pattern was observed in the trauma group. In addition, at the 12th hour after the trauma, IMA levels in the control group showed a pattern comparable to those in the genistein group, but unlike that in the trauma group.

The thiol component containing sulfhydryl (-SH) is important for the antioxidative impact of oxidative processes. Thiol groups of some sulfur-containing amino acids are oxidized by reactive oxygen radicals and are converted reversibly into disulfide bonds. Levels indicated by NT are thiols that are normally found in plasma. The sum of the NTs and thiols formed by the reduction of disulfides is TT. Therefore, the increase in disulfide values represents an increase in the oxidant capacity, and the increase in thiol values represents an increase in the antioxidant capacity [25, 36–38]. Dynamic thiol/disulfide balance has been used frequently in clinical studies because of its antioxidant effect and its effect on apoptosis [5, 36–38]. In the present study, compared with the control group, there was a significant difference between the trauma and genistein groups, particularly on the 7th day (Table 1). There was no significant change between the disulfide values at the baseline and on the 7th day in the control group, whereas disulfide values increased in the trauma group, and showed a marked decrease in the genistein group compared with the baseline (Table 1, Figure 3). Oxidative capacity decreased in the genistein group. NT and TT levels fluctuated with temporal increases and decreases in the trauma and genistein groups. This may be because thiols require more time to achieve a steady state. However, the NT/TT ratio decreased in the control and genistein groups and slightly increased in the trauma group at the 12th hour. When the ratios at the 12th hour and those on the 7th day were compared, no change was observed in the control group, but the ratio decreased in the trauma group and increased in the genistein group (Table 1). Accordingly, although the NT and NT levels alone were not significantly different between the groups, based on the NT/TT ratio we concluded that there was increased antioxidant capacity in the genistein group.

Cox-2 is a conditionally-induced enzyme that is expressed in the event of inflammatory damage [39]. Cox-2 plays a role in the inflammation in secondary damage related to SCI. Cox-2 mRNA and protein expression were increased following SCI, and selective inhibition of Cox-2 led to improved functional outcomes, and neuronal cell death and neuroinflammation were suppressed in experimental models [40]. In addition, Cox-2 expression decreases with the increase in antioxidant defense and decreases under oxidative stress [41, 42]. Genistein inhibits Cox-2 in laboratory studies [43]. The present study found a significant difference in Cox-2 expression between the genistein group and the control and trauma groups (Table 2, Figure 5). This suggests that inflammation in the genistein group is suppressed.

### Table 3. Time-dependent comparison of BBB scores in rats

| Time point | Control group (A) | Trauma group (B) | Genistien group (C) | P       |
|------------|-------------------|------------------|---------------------|---------|
| 12th hour  | 7 (6–7)           | 5 (3–6)          | 5 (2–6)             | 0.006 (x, y) |
| 1st day    | 13 (12–13)        | 11 (9–12)        | 11 (10–12)          | 0.002 (x, y) |
| 3rd day    | 13 (13–13)        | 11 (9–12)        | 12 (11–13)          | 0.001 (x, y, z) |
| 5th day    | 13 (13–13)        | 11 (9–12)        | 13 (12–13)          | <0.001 (x, z) |
| 7th day    | 21 (21–21)        | 18 (14–19)       | 21 (21–21)          | <0.001 (x, z) |

Data are expressed median (interquartile range; Q1, Q3). x, significant difference between groups A and B; y, significant difference between groups A and C; z, significant difference between groups B and C.

BBB, Basso–Beattie and Bresnahan.
compared with that in the trauma group. These results also suggest that genistein had an anti-inflammatory effect on the spinal cord. No overt histopathological difference was found between the groups. This highlights the importance of our immunohistochemical findings, because assessing the inflammatory response from HE staining alone is difficult in neural tissue.

Functional assessment of the rats showed that the baseline functional outcomes were worse in the trauma and genistein groups compared with those in the control group, but rats in the genistein group achieved better functional outcomes than those in the trauma group over time. Moreover, on the 5th day and thereafter, the significant difference between the control and trauma groups persisted, whereas a significant difference between genistein and the control groups was not found. This result showed that better functional outcomes were achieved in the genistein group.

The 7-day follow-up period in the present study was short, limiting its prediction of long-term outcomes of trauma. In addition, the induced model of spinal cord trauma is not a model of severe spinal cord trauma, limiting its prediction of severe SCI outcomes. The study is limited by using the BBB score alone to evaluate function. Although oxidative stress markers are considered to be appropriate for assessment in this model in rats, a problem is that they are highly variable in patients with multiple traumas, and may not be useful in clinical practice.

**Conclusions**

Genistein has antioxidant, protective, and anti-inflammatory effects in an experimental model of SCI in rats. Further study of genistein is warranted as it shows potential as a therapeutic agent for the clinical treatment of SCI.

**Author contributions.** EB, SH, and OFT contributed substantially to the conception and design of the study. EB, SH, ASA, BB, CB, AS, BGO, and BB acquired the data, and all authors contributed to its analysis and interpretation. EB, SH, ASA, CB, AS, BGO, and BB drafted the manuscript and EB, SH, CB, BGO, and OFT critically revised it for important intellectual content. All the authors approved the final version submitted for publication and take responsibility for the statements made in the published article.

**Acknowledgments.** This work was supported by Ankara Yıldırım Beyazıt University Scientific Research Project Fund (Grant No. 4887).

**Conflicts of interest statement.** The authors have each completed and submitted an International Committee of Medical Journal Editors form for disclosure of Potential Conflicts of Interest. None of the authors have any conflict of interest to disclose.

**Data sharing statement.** Statistical summaries of data generated and analyzed for the present report are included in this published article. Further details of the data that support the findings of the present study are available from the corresponding author on reasonable request.

**References**

[1] Liu J, Peng L, Li J. The lipoxin A4 receptor agonist BML-311 alleviates inflammatory injury and oxidative stress in spinal cord injury. Med Sci Monit. 2020; 26:e99883. doi: 10.12659/MSM.919883

[2] Swaroop S, Mahadevan A, Shankar SK, Adlakha YK, Basu A. HSP60 critically regulates endogenous IL-1β production in activated microglia by stimulating NLRP3 inflammasome pathway. J Neuroinflammation. 2018; 15:177. doi: 10.1186/s12974-018-1214-5

[3] Ray SK. Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. Neural Regen Res. 2020; 15:1601–12.

[4] Saghazadeh A, Rezaei N. The role of timing in the treatment of spinal cord injury. Biomed Pharmacother. 2017; 92:128–39.

[5] Singh E, Devasahayam G. Neuregeneration by oxidative stress: a review on prospective use of small molecules for neuroprotection. Mol Biol Rep. 2020; 47:3133–40.

[6] Hall ED. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics. 2011; 8:152–67.

[7] Albayar AA, Roche A, Swiatkowski P, Antar S, Ouda N, Emara E, et al. Biomarkers in spinal cord injury: prognostic insights and future potentials. Front Neurol. 2019; 10:27. doi: 10.3389/fneur.2019.00027

[8] Ydens E, Palmers I, Hendrix S, Somers V. The next generation of biomarker research in spinal cord injury. Mol Neurobiol. 2017; 54:1482–99

[9] Morse LR, Nguyen N, Xu Y, Jha P, Battaglini RA. Circulating PAMM, a novel antioxidant and anti-inflammatory protein, is elevated in acute SCI. J Transl Med. 2020; 18:135. doi: 10.1186/s12974-020-02304-0

[10] Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta. 2012; 1822:675–84.

[11] Oliveira PVC, Couto MR, de Sousa GJ, Peixoto P, Moraes PSA, de Andrade TU, Bissoli NS. Effects of drugs, phytoestrogens, nutrients and probiotics on endothelial dysfunction in the estrogen-deficient state. Curr Pharm Des. 2020; 26:3711–22.

[12] Mizushima Y, Shiomi K, Kuriyama I, Takahashi Y, Yoshida H. Inhibitory effects of a major soy isoflavone, genistein, on human DNA topoisoeraser II activity and cancer cell proliferation. Int J Oncol. 2013; 43:1117–24.

[13] Ghasemi Goorbandi R, Mohammadi MR,Malekzadeh K. Synthesizing efficacious genistein in conjugation with superparamagnetic Fe₃O₄ decorated with bio-compatible carboxymethylated...
chitosan against acute leukemia lymphoma. Biomater Res. 2020; 24:9. doi: 10.1186/s40824-020-00187-2

[14] Milošević VL, Severs WB, Ristić NM, Manojlović-Štojanoski MN, Popovska-Perićinčić FV, Šošić-Jurjević BT, et al. Soy isoflavone effects on the adrenal glands of orchidectomized adult male rats: a comprehensive histological and hormonal study. Histol Histopathol. 2018; 33:843–57.

[15] Lyou S, Kawano S, Yamada T, Okuyama S, Terashima T, Hayase K, et al. Role of estrogen receptors and aromatase on brain protein synthesis rates in ovariecctomized female rats fed genistein. Nutr Neurosci. 2008; 11:155–60.

[16] Soltani Z, Khaksari M, Jafari E, Iranpour M, Shahrorkhi N. Is genistein neuroprotective in traumatic brain injury? Physiol Behav. 2015; 152:26–31.

[17] Khodamoradi M, Asadi-Shekaari M, Esmaeili-Mahani S, Esmaeilpour K, Sheibani V. Effects of genistein on cognitive dysfunction and hippocampal synaptic plasticity impairment in an ovariecctomized rat kainic acid model of seizure. Eur J Pharmacol. 2016; 786:1–9.

[18] Kim DH, Yang WT, Cho KM, Lee JH. Comparative analysis of isoflavone aglycones using microwave-assisted acid hydrolysis from soybean organs at different growth times and screening for their digestive enzyme inhibition and antioxidant properties. Food Chem. 2020; 305:125462. doi: 10.1016/j.foodchem.2019.125462

[19] Bhattarai G, Poudel SB, Kook SH, Lee JC. Anti-inflammatory, anti-oestoclastic, and antioxidant activities of genistein protect against alveolar bone loss and periodontal tissue degradation in a mouse model of periodontitis. J Biomed Mater Res A. 2017; 105:9. doi: 10.1002/jbmr.2993

[20] Semeniuk M, Cere L, Ciriaci N, Bucci-Munoz M, Villanueva SMM, Mottino AD, et al. Regulation of hepatic P-gp expression and activity by genistein in rats. Arch Toxicol. 2020; 94:143–51.

[21] Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research. Exp Physiol. 2020; 105:1459–66.

[22] Erel O. A novel automated direct measurement method for total oxidant status. Clin Biochem. 2005; 38:1103–11.

[23] Erel O, Oran I, Oran B. Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of “N-terminal modification” to “fatty acid occupation” of albumin. Dis Markers. 2017; 2017:5692583. doi: 10.1155/2017/5692583

[24] Giden R, Goldemir MT, Erel O, Buyukaslan H, Karabag H. The relationship between serum thiol levels and thiol/disulfide homeostasis with head trauma in children. Clin Lab. 2018; 64:163–8.

[25] Erel Ö, Erdogán S. Thiol disulfide homeostasis: an integrated approach with biochemical and clinical aspects. Turk J Med Sci. 2020; 50(SI-2):1728–38.

[26] Gündüzetepe Y, Bukan N, Zorlu E, Karaman Y, Andaç Topkan T, Gurbuz N, et al. The evaluation of thiol-disulfite balance, ischemia albumin modification and seruloplasmine as a new oxidative stress in mild cognitive impairment and early stage alzheimer’s disease patients. J Clin Neurosci. 2020; 75:188–94.

[27] Wu W, Wei N, Wang L, Kong D, Shao G, Qin Y, et al. Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition. Oncotarget. 2017; 8:87658–66.

[28] Hua Y, Xu N, Ma T, Liu Y, Xu H, Lu Y. Anti-inflammatory effect of lycopen in experimental spinal cord ischemia injury via cyclooxygenase-2 suppression. Neuroimmunomodulation. 2019; 26:84–92.

[29] David L, Moldovan B, Baldea I, Olteanu D, Bolfa P, Clichici S, Filip GA. Modulatory effects of Cornus sanguinea L. mediated green synthesized silver nanoparticles on oxidative stress, COX-2/NOS2 and NFkB/pNFkB expressions in experimental inflammation in Wistar rats. Mater Sci Eng C Mater Biol Appl. 2020; 110:110709. doi: 10.1016/j.msec.2020.110709

[30] On-Ong-Arj P, Wattanathorn J, Muchimapura S, Thukham-Mee Lyou S, Kawano S, Yamada T, Okuyama S, Terashima T, Hayase K; et al. Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and promotes functional recovery in rats with spinal cord injury. J Neuroinflammation. 2019; 16:283. doi: 10.1186/s12974-019-1658-2

[31] Lee Y-S, Sindhu RK, Lin C-Y, Ehsdaie A, Lin VW, Vaziri ND. Effects of nerve graft on nitric oxide synthase, NAD(P)H oxidase, and antioxidant enzymes in chronic spinal cord injury. Free Radic Biol Med. 2004; 36:330–9.

[32] Vaziri ND, Lee Y-S, Lin C-Y, Lin VW, Sindhu RK. NAD(P)H oxidase, superoxide dismutase, catalase, glutathione peroxidase and nitric oxide synthase expression in subacute spinal cord injury. Brain Res. 2004; 995:76–83.

[33] Kong G, Huang Z, Ji W, Wang X, Liu J, Wu X, et al. The ketone metabolite beta-hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. J Neurotrauma. 2017; 34:2645–55.

[34] Radvan TAM, Fahmy BS, El Emady MFM, Khedir ASEDMA, Osman SH, Elsonbaty ML, et al. Ischemia-modified albumin as a biomarker for prediction of poor outcome in patients with traumatic brain injury: an observational cohort study. J Neurosurg Anesthesiol. 2021; 33:254–7.

[35] Oran I, Oran B. Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of “N-terminal modification” to “fatty acid occupation” of albumin. Dis Markers. 2017; 2017:5692583. doi: 10.1155/2017/5692583

[36] Gündüzetepe Y, Bukan N, Zorlu E, Karaman Y, Andaç Topkan T, Gurbuz N, et al. The evaluation of thiol-disulfite balance, ischemia albumin modification and seruloplasmine as a new oxidative stress in mild cognitive impairment and early stage alzheimer’s disease patients. J Clin Neurosci. 2020; 75:188–94.

[37] Wu W, Wei N, Wang L, Kong D, Shao G, Qin Y, et al. Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition. Oncotarget. 2017; 8:87658–66.

[38] Hua Y, Xu N, Ma T, Liu Y, Xu H, Lu Y. Anti-inflammatory effect of lycopen in experimental spinal cord ischemia injury via cyclooxygenase-2 suppression. Neuroimmunomodulation. 2019; 26:84–92.

[39] David L, Moldovan B, Baldea I, Olteanu D, Bolfa P, Clichici S, Filip GA. Modulatory effects of Cornus sanguinea L. mediated green synthesized silver nanoparticles on oxidative stress, COX-2/NOS2 and NFkB/pNFkB expressions in experimental inflammation in Wistar rats. Mater Sci Eng C Mater Biol Appl. 2020; 110:110709. doi: 10.1016/j.msec.2020.110709

[40] On-Ong-Arj P, Wattanathorn J, Muchimapura S, Thukham-Mee Lyou S, Kawano S, Yamada T, Okuyama S, Terashima T, Hayase K; et al. Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and promotes functional recovery in rats with spinal cord injury. J Neuroinflammation. 2019; 16:283. doi: 10.1186/s12974-019-1658-2

[41] Lee Y-S, Sindhu RK, Lin C-Y, Ehsdaie A, Lin VW, Vaziri ND. Effects of nerve graft on nitric oxide synthase, NAD(P)H oxidase, and antioxidant enzymes in chronic spinal cord injury. Free Radic Biol Med. 2004; 36:330–9.

[42] Vaziri ND, Lee Y-S, Lin C-Y, Lin VW, Sindhu RK. NAD(P)H oxidase, superoxide dismutase, catalase, glutathione peroxidase and nitric oxide synthase expression in subacute spinal cord injury. Brain Res. 2004; 995:76–83.

[43] Kong G, Huang Z, Ji W, Wang X, Liu J, Wu X, et al. The ketone metabolite beta-hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. J Neurotrauma. 2017; 34:2645–55.